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Purpose: To assess the safety of intravenously adminis-
tered gadolinium-based contrast material in sickle cell
disease (SCD) patients.
Materials and Methods: All pediatric and adult SCD
patients evaluated by magnetic resonance imaging (MRI)
at our institution between January 1995 and July 2009
were identified. The medical records of SCD patients who
underwent contrast-enhanced MRI as well as an equal-
sized cohort of SCD patients who underwent unenhanced
MRI were reviewed for adverse (vaso-occlusive and hemo-
lytic) events within 1 week following imaging.
Results: Eight (five mild and three moderate) adverse
events were documented within 1 week following con-
trast-enhanced MRI (38 patients and 61 contrast injec-
tions), while six (five mild and one moderate) similar
events occurred within 1 week following unenhanced MRI
(61 patients and 61 unenhanced MRI examinations). This
difference in the number of adverse events was not statis-
tically significant (odds ratio ¼ 1.4; 95% confidence inter-
val [CI] 0.4, 5.2). No severe adverse event occurred in ei-
ther patient cohort.
Conclusion: Gadolinium-based contrast materials do not
appear to be associated with increased risk of vaso-occlu-
sive or hemolytic adverse events when administered to
SCD patients. Larger, prospective studies using multiple
gadolinium-based contrast materials would be useful to
confirm the results of our investigation.
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THE INTRAVENOUS ADMINISTRATION of gadolin-
ium-based contrast materials (GBCMs) in individuals
with sickle cell disease (SCD) is controversial. It has
been theorized that GBCMs may potentiate sickle
erythrocyte alignment perpendicular to the magnetic
field and increase the risk of vaso-occlusive crisis
(1,2). According to the United States Food and Drug
Administration (US FDA)-approved package insert for
gadoversetamide (Optimark; Covidien, Mansfield, MA)
(1): ‘‘Deoxygenated sickle erythrocytes have been
shown in vitro studies [sic] to align perpendicular to a
magnetic field; this may result in vasoocclusive com-
plications in vivo. The enhancement of magnetic
moment by gadoversetamide may potentiate sickle
erythrocyte alignment.. . . The potential risk of hemoly-
sis after injection of OptiMARK injection in patients
with other hemolytic anemias has not been studied.’’
The FDA-approved package insert for gadoteridol (Pro-
Hance; Bracco Diagnostics, Princeton, NJ) (2) con-
tains similar statements, while analogous information
has been removed from the package inserts of other
GBCMs.
Review of the literature to date reveals no docu-
mented in vivo vaso-occlusive or hemolytic complica-
tion related to GBCM in an individual with SCD. A
few small studies of SCD patients undergoing con-
trast-enhanced magnetic resonance imaging (CE-MRI)
have reported no adverse effects related to GBCM
administration (3–7).
The purpose of this study was to retrospectively
evaluate the safety of intravenously administered
GBCMs in children and adults with SCD.
MATERIALS AND METHODS
This study was Institutional Review Board (IRB)-
approved and performed in a Health Insurance Port-
ability and Accountability Act (HIPAA, USA)-compliant
manner. Patient informed consent was not required
based on institutional policy and the retrospective na-
ture of our investigation.
All pediatric and adult SCD patients evaluated by
MRI between January 1, 1995 and July 31, 2009
within the University of Michigan Health System were
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identified by searching available institutional elec-
tronic medical records. Individuals with HbSS, HbSC,
HbSD, and HbS-thalassemia hemoglobinopathies
(both hemoglobin genes are abnormal) were included
in this search, while individuals with sickle cell ‘‘trait’’
(one of two hemoglobin genes is normal) were inten-
tionally excluded.
Electronic medical records of SCD patients who
underwent CE-MRI were reviewed by a single author
for adverse events within the 1-week period following
GBCM administration. Electronic medical records
from an equal-sized cohort of SCD patients who had
undergone unenhanced MRI were also reviewed for
adverse events within the 1-week period following
imaging (also by a single author). This control patient
cohort was established in the following manner. All
SCD patients who were evaluated by unenhanced MRI
during the study period were placed in consecutive
numerical order by date of birth. Using a computer-
ized randomization program (www.random.org), 61
numbers (corresponding to subjects) were randomly
identified. The 1-week period following each of these
subjects’ most recent unenhanced MRI examination
was chosen for review.
Medical records were specifically reviewed for vaso-
occlusive (eg, acute chest syndrome, bone pain crisis,
deep venous thrombosis, stroke, etc.) and hemolytic
events. Potential sickle cell disease-related vaso-
occlusive and hemolytic adverse events were defined
as being mild, moderate, or severe based on a novel
classification system (Table 1).
RESULTS
Thirty-eight SCD patients underwent 61 CE-MRI
examinations during our study period. The mean age
of these patients at the time of CE-MRI was 19.4
years (range, 2–55 years). Twenty-nine contrast injec-
tions were performed on male patients, while 32 con-
trast injections were performed on female patients.
Twenty-seven SCD patients had one CE-MRI exami-
nation during the study period, five had two examina-
tions, two had three examinations, two had four
examinations, and two had five examinations.
Seventy-five SCD patients underwent 188 unen-
hanced MRI examinations during the study period.
From these 188 unenhanced MRI examinations, 61
examinations (from 61 patients) were selected using
the method described. The mean age of these patients
at the time of their unenhanced MRI examination
included in our study was 20.4 years (range, 11
months to 66 years). Twenty-nine of the unenhanced
MRI examinations were performed on male patients,
while 32 were performed on female patients.
Twenty-two SCD patients were included in both the
CE-MRI and selected unenhanced MRI cohorts (mean-
ing these patients had undergone both CE-MRI and
unenhanced MRI at different times during the study
period). There were no statistically significant differen-
ces between the ages (P > 0.6) and genders (P ¼ 1.0)
of patients in the two subject groups.
The majority of MRI examinations included in both
subject groups were performed on individuals with
HbSS hemoglobinopathy (classic sickle cell disease).
Fifty-four CE-MRI examinations were performed in
HbSS patients, while 55 unenhanced MRI examina-
tions were performed in HbSS patients. A small num-
ber of examinations included in both the CE-MRI and
unenhanced MRI subject groups had other hemoglobi-
nopathies (two MRI examinations performed on HbSC
patients in both cohorts, five MRI examinations per-
formed on Hb-thalassemia patients in the CE-MRI
cohort, and four MRI examinations performed on Hb-
thalassemia patients in the unenhanced MRI cohort).
In the CE-MRI subject group, six patients received
intravenous Magnevist (gadopentetate dimeglumine;
Bayer HealthCare Pharmaceuticals, Wayne, NJ), while
four received MultiHance (gadobenate dimeglumine;
Bracco Diagnostics, Princeton, NJ). Unfortunately, the
GBCM administered to 51 patients was not docu-
mented in the final imaging report. These 51 patients
could have received one of four possible contrast
agents used during the study period (including gado-
pentetate dimeglumine, gadobenate dimeglumine,
gadoteridol, or gadodiamide).
No documented vaso-occlusive or hemolytic adverse
event occurred within 24 hours of imaging in either
patient cohort. Eight adverse events (in 61 injections/
38 patients) occurred within the 1-week period follow-
ing GBCM administration in the CE-MRI patient group.
Five (63%) of these adverse events were mild, while
three (37%) were moderate in severity (Table 2). Two of
these adverse events (one mild and another moderate)
occurred in the same patient 4 years apart.
Six adverse events (in 61 examinations/61 patients)
occurred within the 1-week period following imaging
in the unenhanced MRI patient cohort. Five (83%) of
these adverse events were mild, while one (17%) was
moderate in severity (Table 3). Four of these subjects
also experienced adverse events following earlier or
subsequent CE-MRI.
The difference in the number of adverse events
between the two subject groups was not statistically
significant (odds ratio ¼ 1.4; 95% confidence interval
[CI] 0.4, 5.2). Regarding moderate adverse events, the
difference in number between the two subject groups
also was not statistically significant (P > 0.6; Fisher’s
exact test). No hemolytic (of any severity) or severe
vaso-occlusive adverse event was documented in ei-
ther the CE-MRI or unenhanced MRI subject group.
Table 1
Classification Sickle Cell Disease-Related Adverse
Events by Severity
Mild 1. Vaso-occlusive crisis managed without
hospital admission.
2. Exacerbation of preexisting inpatient
vaso-occlusive crisis.
3. Hemolytic event not requiring blood
transfusion.
Moderate 1. Vaso-occlusive crisis requiring hospital
admission for management.
2. Hemolytic event requiring blood transfusion.
Severe 1. Life-threatening vaso-occlusive crisis.
2. Life-threatening hemolytic event.
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DISCUSSION
MRI is frequently used to assess patients with SCD
for disease-related complications. For example, MRI of
the brain is commonly used to assess for sickle cell
vasculopathy (secondary Moyamoya disease or Moya-
moya syndrome) and stroke (8), while MRI of the mus-
culoskeletal system may be used to attempt to differ-
entiate acute osseous infarction from osteomyelitis
(3). While unenhanced MRI may be adequate to con-
firm certain SCD-related complications, other compli-
cations may benefit from the intravenous administra-
tion of a GBCM in order to obtain a precise diagnosis.
A few small studies have administered GBCMs to
SCD patients without reported vaso-occlusive or he-
molytic adverse events. Umans et al (3) administered
GBCM to nine SCD patients in an attempt to distin-
guish areas of osteomyelitis from medullary bone in-
farction. Westwood et al (4) administered GBCM to 30
SCD patients in order to assess delayed myocardial
enhancement related to regional cardiac fibrosis
(sickle cell cardiomyopathy). Several small studies
have used GBCM to assess cerebral perfusion in
sickle cell disease (5–7), as 17% of SCD patients ex-
perience silent cerebral infarctions (8).
Our investigation comparing SCD patients who
underwent CE-MRI to SCD patients who underwent
MRI without intravenous contrast material demon-
strated no significant difference in the frequency of
vaso-occlusive and hemolytic adverse events. At our
institution, almost as many SCD patients experience
adverse events following unenhanced MRI as do fol-
lowing CE-MRI. In fact, four of seven SCD patients
who experienced adverse events following CE-MRI
also experienced adverse events following unenhanced
MRI. Based on our results, we believe it is likely that
most (if not all) of the eight adverse events observed
following CE-MRI would have occurred even if a
GBCM had not been administered.
Our results are in agreement with a recent addition
to the American College of Radiology’s Manual on
Contrast Media (v. 7) (9). In a recently added section,
the authors of this document state ‘‘. . .it is our opinion
that any special risk to sickle cell patients from IV
administered GBCM at currently approved dosages
must be extremely low, and there is no reason to
withhold these agents from patients with sickle cell
disease. However, as in nonsickle cell disease
patients, GBCM should be administered only when
clinically indicated’’ (9).
We believe the idea that GBCMs can ‘‘potentiate’’
sickle erythrocyte alignment perpendicular to a mag-
netic field in vivo based on local magnetic field
changes at the cellular level and thereby resulting in
an acute vaso-occlusive crisis may be based on a
somewhat flawed understanding of the physics
involved. GBCM T1 shortening is in part established
by the rotational correlation times, or tumbling rates,
of gadolinium chelates as they interact with water at
the molecular level. Therefore, it is likely that the mo-
lecular-sized magnetic fields associated with these
administered contrast agents at standard approved
doses are actually changing several million times per
second. Based on this fact, sickle erythrocyte align-
ment in a specific orientation due to GBCM exposure
is quite unlikely. This information along with the ab-
sence of reports of adverse events related to these
Table 2
Sickle Cell Disease-Related Adverse Events in 38 Patients Undergoing 61 Contrast-Enhanced MRI Examinations
Severity Age Gender Hem Day Adverse Event
Mild 8 M HbSC 2 worsening of inpatient bone pain crisis
Mild 16 F HbSS 2 worsening of inpatient bone pain crisis
Mild 25 F HbSS 2 worsening of inpatient acute chest syndrome
Mild 16 M HbSS 7 bone pain crisis, outpatient management*
Mild 27 M HbSS 7 bone pain crisis, outpatient management
Moderate 2 M HbSS 2 dactylitis, hospital admission & inpatient management
Moderate 23 M HbS-Thal 2 bone pain crisis, hospital admission & inpatient management
Moderate 12 M HbSS 6 LE DVT, hospital admission & inpatient management*
Hem ¼ hemoglobinopathy; M ¼ male; F ¼ female; LE DVT ¼ lower extremity deep venous thrombosis.
Day ¼ number of days following CE-MRI adverse event occurred (day of imaging examination ¼ day 1).
*Same patient.
Table 3
Sickle Cell Disease-Related Adverse Events in 61 Patients Undergoing 61 Unenhanced MRI Examinations
Severity Age Gender Hem Day Adverse Event
Mild 16 F HbSS 2 worsening of inpatient bone pain crisis*
Mild 19 M HbSS 3 worsening of inpatient bone pain crisis
Mild 25 M HbSS 3 worsening of inpatient acute chest syndrome
Mild 25 F HbSS 5 new acute chest syndrome as inpatient*
Mild 16 M HbSS 7 bone pain crisis, outpatient management*
Moderate 33 M HbSS 4 bone pain crisis, hospital admission & inpatient management*
Hem ¼ hemoglobinopathy; M ¼ male; F ¼ female.
Day ¼ number of days following unenhanced MRI adverse event occurred (day of imaging examination ¼ day 1).
*Patient also experienced adverse event following CE-MRI.
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contrast agents in SCD patients may be responsible,
at least in part, for recent modifications to the pack-
age inserts of several GBCMs regarding their use in
individuals with hemoglobinopathies.
Our study has a few limitations. First, it was a ret-
rospective review of selected patients and not prospec-
tive or randomized in design. Second, our study
included a relatively small number of patients, as
only 61 GBCM administrations occurred in SCD
patients during our study period. Availability of a
greater number of GBCM injections would decrease
the potential for making a type II error (b error).
It is also difficult to definitively establish that an
adverse reaction is directly related to GBCM injection
(especially as SCD patients undergoing unenhanced
MRI clearly experience similar adverse events). At
least some (if not all) adverse events experienced by
individuals undergoing both CE-MRI and unenhanced
MRI most likely would have occurred in the absence
of imaging, although some have theorized that place-
ment of sickle erythrocytes in a magnetic environment
in the absence of GBCM may, in and of itself, increase
the risk of vaso-occlusive crisis based on in vitro
research (10,11). Therefore, while our study does not
allow us to make any conclusions about whether ex-
posure of SCD patients to the magnetic field of MRI
leads to adverse events, we can conclude, based on
our study, that the use of GBCMs alone likely does
not appear to provide added risk. Finally, our study is
unable to account for other possible causes of adverse
events following imaging, such as preceding or subse-
quent dehydration or hypoxia.
In conclusion, our study suggests that GBCM
administration does not appear to be associated with
increased frequency of adverse events in SCD patients
undergoing CE-MRI in comparison with patients
undergoing going unenhanced MRI. To date, there is
no evidence to support the withholding of these con-
trast agents from SCD patients when deemed medi-
cally necessary. However, further investigation of this
subject with larger patient cohorts and multiple
GBCMs would be helpful to definitively establish the
safety of these contrast agents in this patient
population.
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